drugset / Trial / NCT07848191
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)
Timeline
- Start
- 2026-09
- Primary completion
- 2027-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | Oral |
| Subject | Pioglitazone | Small molecule | 45 mg | Oral |
| Subject | Resmetirom | Small molecule | 80 mg | Oral |
| Subject | Resmetirom | Small molecule | 100 mg | Oral |